Today several people have reminded me that it’s Canada Day and also the Independence Day weekend in the US. Although I’m British and celebrate neither, there will be a short hiatus from blogging in honour of my Canuck and American friends.
We’ll be working unfortunately, such is the life as a consultant, with deadlines galore due next week!
For those of you anxious not to miss anything hot on the social media front, check out this article from BioWorld on Biotechs and Social Media, kindly sent in by Drs Brian Orelli and Al Lalani.
Here’s an interesting quote from the research:
In an informal BioWorld Today survey, more than 44 percent (95) of the 215 respondents said their firms are not engaging in social media. The No. 1 reason, listed by 42 percent, was that social media “was not the place for us.”
I can understand that approach completely – social media is about engagement and sharing; dealing with the challenges of unhappy patients complaining publicly online via social media puts Pharma in an awkward spot regarding how to handle issues that may arise:
The biggest concern the companies had with social media was how to balance the risks and benefits. That balance was cited by nearly half the respondents. Other top concerns were dealing with third-party comments and opening themselves to liability.
The short article is well worth reading. It reminds me of the dilemma a client recently expressed:
“Do we continue to focus strategically on research & development, trying to find cures for cancer, or do we allow ourselves to be distracted by other issues like shiny new tools and tactics? I only have so much time in a day.”
Fair point indeed and a dilemma that many of you will already be discussing offline. There is no right or wrong answer – you can only do the best you can with the time and resources you have available.
In the meantime, Pharma Strategy Blog will resume as usual on Tuesday.
Happy Holidays to all!